KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ginkgo Bioworks Holdings (DNA) Net Margin (2020 - 2025)

Ginkgo Bioworks Holdings' Net Margin history spans 6 years, with the latest figure at 241.8% for Q4 2025.

  • For Q4 2025, Net Margin rose 345.0% year-over-year to 241.8%; the TTM value through Dec 2025 reached 183.81%, up 5713.0%, while the annual FY2025 figure was 183.81%, 5713.0% up from the prior year.
  • Net Margin reached 241.8% in Q4 2025 per DNA's latest filing, down from 207.93% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 63.34% in Q3 2024 to a low of 1080.85% in Q4 2021.
  • Average Net Margin over 5 years is 351.17%, with a median of 243.52% recorded in 2024.
  • Peak YoY movement for Net Margin: tumbled -94193bps in 2021, then soared 90475bps in 2022.
  • A 5-year view of Net Margin shows it stood at 1080.85% in 2021, then soared by 84bps to 176.1% in 2022, then crashed by -246bps to 609.1% in 2023, then soared by 60bps to 245.25% in 2024, then increased by 1bps to 241.8% in 2025.
  • Per Business Quant, the three most recent readings for DNA's Net Margin are 241.8% (Q4 2025), 207.93% (Q3 2025), and 121.56% (Q2 2025).